N,N-bis-(2-chloro-ethyl)-glycine amide | 2482-85-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-bis-(2-chloro-ethyl)-glycine amide
• 英文别名: N,N-Bis-(2-chlor-aethyl)-glycin-amid；Acetamide, 2-(bis(2-chloroethyl)amino)-；2-[bis(2-chloroethyl)amino]acetamide
• CAS: 2482-85-1
• 化学式: C₆H₁₂Cl₂N₂O
• 分子量: 199.08
• InChiKey: UIUAGJLYQBSJSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N,N-bis-(2-chloro-ethyl)-glycine nitrile; hydrochloride 在 硫酸 作用下， 生成 N,N-bis-(2-chloro-ethyl)-glycine amide
  参考文献：
  名称：

  Izumi, Pharmaceutical Bulletin, 1954, vol. 2, p. 275,278

  摘要：

  DOI：

文献信息

• Frangible compounds for pathogen inactivation
  申请人：Cerus Corporation

  公开号：US20040029897A1

  公开（公告）日：2004-02-12

  Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

  描述了用于使材料中的病原体失活的化合物和方法，包括用于使生物材料中的病原体失活的组合物和方法，例如红细胞制备物和血浆。这些化合物和方法可用于处理用于体外或体内使用的材料，如临床测试或输血。这些化合物被设计为特异性结合和与核酸反应，然后降解形成分解产物。降解反应最好比与核酸的反应慢。
• [EN] FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION<br/>[FR] COMPOSES FRANGIBLES POUR INACTIVATION PATHOGENE
  申请人：CERUS CORPORATION

  公开号：WO1998030545A1

  公开（公告）日：1998-07-16

  (EN) Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for $i(in vitro) or $i(in vivo) use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.(FR) La présente invention concerne des composés et des procédés permettant d'inactiver des pathogènes dans des matériaux comportant des compositions et des procédés d'inactivation de pathogènes dans des matériaux biologiques tels que des préparations de globules rouges et de plasma. Les compositions et les procédés peuvent être utilisés pour le traitement de matériaux destinés à une utilisation $i(in vitro) ou $i(in vivo) telle qu'essai clinique ou transfusion. Les composés sont conçus de manière à se lier spécifiquement à un acide nucléique et à réagir avec ledit acide et, ensuite, à se dégrader sous forme de produits de fractionnement. La réaction de dégradation est, de préférence plus lente que la réaction avec l'acide nucléique.

  (中文) 本文描述了用于使材料中的病原体失活的化合物和方法，包括用于在生物材料中使病原体失活的组合物和方法，例如红细胞制备和血浆。这些化合物和方法可用于处理用于体内或体外使用的材料，例如临床测试或输血。这些化合物旨在特异性地结合并与核酸反应，然后分解形成分解产物。分解反应最好比与核酸的反应慢。
• Frangible Compounds for Pathogen Inactivation
  申请人：Cerus Corporation

  公开号：EP1364944A1

  公开（公告）日：2003-11-26

  Compound and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

  描述了用于灭活材料中病原体的化合物和方法，包括用于灭活红细胞制剂和血浆等生物材料中病原体的组合物和方法。这些化合物和方法可用于处理体外或体内使用的材料，如临床测试或输血。这些化合物可与核酸发生特异性结合和反应，然后降解形成分解产物。降解反应最好比与核酸的反应慢。
• Inhibiting proliferation of arterial smooth muscle cells
  申请人：——

  公开号：US20010036948A1

  公开（公告）日：2001-11-01

  The present invention provides methods and compositions for inhibiting the proliferation of smooth muscle cells at a site of vascular injury. The methods include intravascular administration of a reactive compound to the site of injury, without the requirement for activation or sustained release of the compound.

  本发明提供了抑制血管损伤部位平滑肌细胞增殖的方法和组合物。这些方法包括在血管内向损伤部位施用反应性化合物，而不需要激活或持续释放化合物。
• Methods for quenching pathogen inactivators in biological materials
  申请人：Cerus Corporation

  公开号：US20020028432A1

  公开（公告）日：2002-03-07

  Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group. In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione. Biological materials which may be treated include whole blood, red blood cells, blood plasma, and platelets. The methods permit inhibition of the modification of red blood cells in red blood cell containing materials during pathogen inactivation.

  本发明提供了淬灭生物材料中病原体灭活化合物不希望发生的副反应的方法。在一个特定的实施方案中，提供了淬灭病原体灭活化合物不希望发生的副反应的方法，该化合物包括一个亲电基团或能够形成亲电基团的官能团。在本实施方案中，用病原体灭活化合物和淬灭剂处理材料，其中淬灭剂包括能与亲电基团发生共价反应的亲核官能团。病原体灭活化合物上的亲电基团最好是非放射性阳离子基团。在一个实施方案中，病原体灭活化合物包括核酸结合配体和芥子气基团，其中芥子气基团能够原位反应形成亲电基团。首选淬灭剂是硫醇，如谷胱甘肽。可处理的生物材料包括全血、红细胞、血浆和血小板。这些方法可以在病原体灭活过程中抑制含红细胞材料中红细胞的修饰。